PubMed · 8825571
Canine osteosarcoma: amputation and chemoimmunotherapy.
Abstract
Canine osteosarcoma is a highly metastatic cancer commonly seen in large breed dogs. At the time of diagnosis, approximately 90% to 95% of the dogs have established micrometastases. Dogs undergoing amputation alone have a median survival time of 3 to 4 months. Amputation followed by cisplatin chemotherapy increases median survival times to 9 to 11 months. When dogs are treated with amputation and cisplatin, followed by immunotherapy (with liposome-encapsulated muramyl tripeptide phosphatidylethanolamine), median survival times increase to 14.4 months, the longest reported median survival time for dogs with osteosarcoma treated by amputation and any form of adjuvant therapy.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
E G MacEwen, I D Kurzman. 1996. Canine osteosarcoma: amputation and chemoimmunotherapy.. https://doi.org/10.1016/s0195-5616(96)50011-2
Cite the original work for its findings. Save a collection to share your selection of sources.